Literature DB >> 20807189

The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.

Shivshankar Thanigaimani1, Ganessan Kichenadasse, Arduino A Mangoni.   

Abstract

Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20807189     DOI: 10.2174/157016111795495503

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  12 in total

Review 1.  Vascular endothelial growth factor from embryonic status to cardiovascular pathology.

Authors:  Mohsen Azimi-Nezhad
Journal:  Rep Biochem Mol Biol       Date:  2014-04

2.  Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.

Authors:  Patricia M LoRusso; Smitha Krishnamurthi; Hagop Youssoufian; Nancy Hall; Floyd Fox; Aruna Dontabhaktuni; Dmitri Grebennik; Scot Remick
Journal:  Invest New Drugs       Date:  2013-08-01       Impact factor: 3.850

Review 3.  Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System.

Authors:  Paola Maria Cutroneo; Claudia Giardina; Valentina Ientile; Simona Potenza; Laura Sottosanti; Carmen Ferrajolo; Costantino J Trombetta; Gianluca Trifirò
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

4.  Effect of oral niacin on central retinal vein occlusion.

Authors:  Michael W Gaynon; Yannis M Paulus; Ehsan Rahimy; Janet L Alexander; Sam E Mansour
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-04       Impact factor: 3.117

5.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

6.  Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling.

Authors:  Neil M Fournier; Boyoung Lee; Mounira Banasr; Maha Elsayed; Ronald S Duman
Journal:  Neuropharmacology       Date:  2012-05-10       Impact factor: 5.250

Review 7.  Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.

Authors:  Peter K Kaiser; Alan F Cruess; Peter Bogaert; Kamlesh Khunti; Simon P Kelly
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-12       Impact factor: 3.117

8.  Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.

Authors:  Alejandro R Chade; Nicholas J Stewart; Patrick R Peavy
Journal:  Kidney Int       Date:  2013-12-18       Impact factor: 10.612

Review 9.  The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention.

Authors:  Huzefa Vahora; Munawwar Ali Khan; Usama Alalami; Arif Hussain
Journal:  J Cancer Prev       Date:  2016-03-30

10.  Increase in peripheral blood mononuclear cell Toll-like receptor 2/3 expression and reactivity to their ligands in a cohort of patients with wet age-related macular degeneration.

Authors:  Yi Zhu; Liang Liang; Dan Qian; Hongsong Yu; Peizeng Yang; Bo Lei; Hui Peng
Journal:  Mol Vis       Date:  2013-08-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.